A detailed history of Truvestments Capital LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Truvestments Capital LLC holds 500 shares of AUTL stock, worth $1,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Holding current value
$1,030
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 07, 2025

BUY
$2.18 - $4.8 $1,090 - $2,400
500 New
500 $1,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $187M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Truvestments Capital LLC Portfolio

Follow Truvestments Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truvestments Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Truvestments Capital LLC with notifications on news.